ArriVent BioPharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 weeks.
- Its last 3 Sell calls were followed by a 23% average decline over the next quarter.
- Recent price momentum is -55.8% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 11.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -58.9% | Better than 8% |
| Return on invested capital | -62.8% | Better than 5% |
Momentum D-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -63.9% | Better than 2% |
| 6-month return | -60.6% | Better than 4% |
| 12-month return (ex latest month) | -5.7% | Better than 26% |
| Distance below 52-week high | 70.6% | Better than 6% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 12.8x | Better than 95% |
| Debt to assets | 0.0% | Better than 100% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 166.2% | Better than 92% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 11.26
- Open
- 11.00
- Day range
- 10.38 - 11.35
- Avg price
- 10.75
- Volume
- 1.05M
- Turnover
- 11.33M
- Turnover ratei
- 3.34%
- Volume ratioi
- 0.92
- Amplitudei
- 8.62%
- 52-week rangei
- 10.33 - 35.83
Valuation
- P/Ei
- -2.44
- P/E (TTM)i
- -2.92
- P/Bi
- 1.38
- EPSi
- -4.32
- Book value / shi
- 7.61
- Net profit
- -223.44M
- Net assets
- 393.46M
Share structure
- Market cap
- 544.13M
- Float capi
- 331.50M
- Shares out
- 51.72M
- Float sharesi
- 31.51M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-01-26
70.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+6.49M net over the window
Short interest
- Shares short
- 5.80M
- % of floati
- 11.76%
- Days to coveri
- 3.43
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of ArriVent BioPharma (AVBP)?
ArriVent BioPharma last traded at 10.52. This page shows a periodic quote snapshot. Check the displayed quote time.
What is ArriVent BioPharma's market cap?
About 544.13M.
What is the P/E ratio of ArriVent BioPharma?
The trailing twelve-month P/E is -2.92. The Valuation tab shows it against the stock's own five-year range.
Does ArriVent BioPharma pay a dividend?
ArriVent BioPharma does not currently pay a regular dividend.
Is ArriVent BioPharma a buy according to analysts?
The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 28.00, which implies 166.2% upside from the current price. This is not investment advice.
What is ArriVent BioPharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ArriVent BioPharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ArriVent BioPharma discussion 0 comments